ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Lawsuits Blame Diabetes Drug Invokana for Amputations


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Man standing with amputated leg

People who say they had to undergo amputations below the knee after taking the Type 2 diabetes drug Invokana are filing lawsuits against Johnson & Johnson’s Janssen Pharmaceuticals.

Injured parties have filed Invokana lawsuits in state court in New Jersey, where Johnson & Johnson is based, and in federal multidistrict litigation, which is also being managed in New Jersey.

Multidistrict litigation (MDL) is a way for federal courts to streamline the management of large numbers of lawsuits filed around the country involving the same issues. When MDLs are created, all the cases are transferred to a single judge, who presides over the initial trials.

In the case of Invokana, 952 complaints alleging various injuries were pending as of Dec. 18, 2017, according to court records. The majority of the lawsuits involve injuries other than amputations, including ketoacidosis, infections, stroke and kidney injuries.

A federal court panel created the Invokana MDL on Dec. 7, 2016.

The link to amputations was highlighted in May 2017 when the U.S. Food and Drug Administration required the manufacturer to include a black box warning — the most serious kind — regarding amputations. The FDA’s decision followed two large clinical trials that showed people who took the drug having twice as many leg and foot amputations as people given a placebo.

Drugwatch legal partner Weitz & Luxenberg began accepting Invokana amputation cases in June 2017.

Tennessee Woman Loses Toe

The most recent federal lawsuit linking Invokana to amputations involves Gadsden, Tenn., resident Bonnie Hamm, who filed a lawsuit Dec. 26, 2017.

Hamm began using Invokana after it was prescribed to treat her diabetes in May 2016, according to the complaint. Invokana is a sodium-glucose cotransporter 2 (SGLT2) inhibitor drug. It works by stopping the kidneys from reabsorbing glucose to control blood sugar levels.

A month after prescribing her Invokana, Hamm’s doctor prescribed Invokamet, which combines canagliflozin, the active ingredient in Invokana, with metformin.

Surgeons ultimately amputated the first toe of Hamm’s right foot on Jan. 25, 2017, according to the lawsuit.

The lawsuit accuses Janssen of failing to adequately warn patients and doctors about the risks of taking the drug and the monitoring required to ensure patient safety.

Iowa and Alabama Men Sue in State Court

Lawyers filed two lawsuits in New Jersey Superior Court in Middlesex County on behalf of patients who underwent amputations after taking Invokana, according to a Jan. 2 news release.

Plaintiff Robert E. Shook, 60, of Alabama began treatment with the drug in January 2015 and underwent left foot and below-the-knee leg amputations on Dec. 15, 2015, and Jan. 15, 2016, the news release said.

Michael A. Wilkinson, 53, of Iowa, started taking Invokana in April 2015 and had his right leg amputated below the knee on Dec. 14, 2015, according to the news release by the Parker Waichman law firm.

In addition, attorneys filed four Invokana amputation lawsuits in federal court on Oct. 20, 2017.

Elaine Silvestrini
Written By Elaine Silvestrini Writer

Elaine Silvestrini is an award-winning journalist with 30 years of experience covering state and federal court systems. She joined Drugwatch in 2017. Her coverage for Drugwatch has been cited in the CDC’s Public Health Law News and the USA Today Network. Some of her qualifications include:

  • Centers for Disease Control and Prevention certificates in Health Literacy
  • Experience as an assistant investigator for the Federal Public Defender
  • Loyola Law School Journalist Law School Fellowship
Edited By
Emily Miller
Emily Miller Managing Editor

8 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Cision PR Newswire. (2018, January 2). Lawsuits filed against J&J Related to its Drug Invokana. Retrieved from
  2. In Re: Invokana (Canagliflozin) Products Liability Litigation. (2017, October 20). Mildred Moore v. Janssen Pharmaceuticals et al. Direct Filed Complaint. Retrieved from
  3. In Re: Invokana (Canagliflozin) Products Liability Litigation. (2017, October 20). Robert Johnson et al v. Janssen Pharmaceuticals et al. Direct Filed Complaint. Retrieved from
  4. In Re: Invokana (Canagliflozin) Products Liability Litigation. (2017, October 20). Robin Pepper v. Janssen Pharmaceuticals et al. Direct Filed Complaint. Retrieved from
  5. In Re: Invokana (Canagliflozin) Products Liability Litigation. (2017, October 20). Jeffrey Baker et al v. Janssen Pharmaceuticals et al. Direct Filed Complaint. Retrieved from
  6. U.S. District Court District of New Jersey. (2017, January). In Re: Invokana (Canagliflozin) Products Liability Litigation. Case Management Order #1 Retrieved from
  7. Judicial Panel on Multidistrict Litigation. (2017, December 18). MDL Statistics Report Distribution of Pending MDL Dockets by District. Retrieved from
  8. U.S. Food and Drug Administration. (2017, May 16). Drug Safety Communications. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617